Topic Hub
18 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 18 of 18 clinical reviews.
A clinical comparison of NMN/NR (nicotinamide mononucleotide/riboside) and low-dose naltrexone (LDN) for longevity: mechanisms, evidence, combination rationale, and safety risks. Reviewed by the HealthRX medical team.
Read clinical reviewA head-to-head clinical comparison of NMN/NR (nicotinamide mononucleotide/riboside) versus compounded low-dose naltrexone for long-term durability, covering trial data, mechanism, dose, and which patients are likely to respond best over time.
Read clinical reviewA detailed clinical comparison of NMN/NR (nicotinamide mononucleotide/riboside) and low-dose naltrexone (LDN), covering mechanism, trial data, real-world outcomes, and how to choose between them for longevity and immune support.
Read clinical reviewA clinical comparison of NMN/NR (nicotinamide mononucleotide/riboside) and low-dose naltrexone across special populations including older adults, autoimmune patients, cancer survivors, and metabolic disease, with dosing, evidence grades, and switching criteria.
Read clinical reviewA clinical comparison of NMN/NR (nicotinamide mononucleotide/riboside) and low-dose naltrexone titration protocols, side-effect profiles, and tolerability data to help patients and prescribers choose the right longevity intervention.
Read clinical reviewA clinical comparison of NMN/NR (nicotinamide mononucleotide/riboside) and low-dose naltrexone (LDN) for longevity and immune modulation, including what the evidence says about switching when one stops working.
Read clinical reviewA clinical comparison of rapamycin (sirolimus) and low-dose naltrexone (LDN) for longevity, including the mechanistic rationale for combining them, real trial data, dosing, and a frank look at risks.
Read clinical reviewA direct clinical comparison of rapamycin (sirolimus) and low-dose naltrexone (LDN) for long-term durability of effect, covering trial evidence, mechanisms, switching criteria, and dosing in longevity and immune contexts.
Read clinical reviewA clinician-reviewed comparison of rapamycin (sirolimus) and low-dose naltrexone (LDN) for longevity and immune modulation, drawing on real-world evidence, named trials, and dosing data.
Read clinical reviewA clinical comparison of rapamycin (sirolimus) and low-dose naltrexone (LDN) in special populations, elderly, autoimmune, cancer, metabolic, and immunocompromised patients, with trial data, dosing tables, and switching guidance.
Read clinical reviewA head-to-head clinical comparison of rapamycin (sirolimus) and low-dose naltrexone (LDN) titration protocols, tolerability profiles, and longevity-medicine use cases, with primary-source citations throughout.
Read clinical reviewA head-to-head clinical comparison of rapamycin (sirolimus) and NMN/NR (nicotinamide mononucleotide/riboside) for longevity, covering mechanisms, trial data, real-world evidence, side-effect profiles, and how to choose between them.
Read clinical reviewA clinician-reviewed comparison of rapamycin (sirolimus) versus NMN/NR (nicotinamide mononucleotide/riboside) for longevity across special populations including older adults, diabetics, cancer survivors, women on HRT, and immunocompromised patients. Includes trial data, dosing guidance, and switching criteria.
Read clinical reviewA clinical comparison of rapamycin (sirolimus) and NMN/NR (nicotinamide mononucleotide/riboside) for longevity, including how to recognize failure and when to switch or combine.
Read clinical reviewA head-to-head clinical comparison of rapamycin (sirolimus) and NMN/NR (nicotinamide mononucleotide/riboside) for long-term longevity durability, covering mechanism, trial data, and switching decisions.
Read clinical reviewA head-to-head clinical comparison of rapamycin (sirolimus) and NMN/NR (nicotinamide mononucleotide/riboside) titration protocols, side-effect profiles, and tolerability data to help you and your clinician choose the right longevity regimen.
Read clinical reviewA clinical comparison of rapamycin (sirolimus) and low-dose naltrexone (LDN) for longevity and immune modulation, including what evidence supports switching when one drug stops working.
Read clinical reviewA clinical comparison of rapamycin (sirolimus) and NMN/NR (nicotinamide mononucleotide/riboside) for longevity, including mechanism differences, trial data, combination rationale, and real risks.
Read clinical review